ヒト免疫不全ウイルス関連がんにおける免疫チェックポイント阻害剤の安全性と有効性:体系的な範囲レビュー
Ahmed D Alatawi1, Amirah B Alaqyl2, Reema J Alalawi2
1Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka 72341, Saudi Arabia.
Diseases (Basel, Switzerland)
|August 27, 2025
まとめ
免疫チェックポイント阻害剤 (ICI) は,管理可能な副作用と安定したHIVウイルスの負荷を持つHIVに関連した癌の治療に有望である. 患者の選択を最適化し,HIV感染者 (PLWH) の治療ガイドラインを確立するには,さらなる研究が必要です.
科学分野:
- 腫瘍学
- 免疫学
- 感染症
背景:
- HIV感染者 (PLWH) は悪性腫瘍のリスクが高い.
- 癌のPLWHに対する免疫療法へのアクセスは,安全性と有効性の懸念のために制限されています.
研究 の 目的:
- HIV関連がんにおける免疫チェックポイント阻害剤 (ICI) の有効性と安全性を体系的に検討する.
- 患者のアウトカム,安全性プロファイル,HIV状態への影響を分析する.
主な方法:
- 2025年1月までのPubMed,Scopus,Web of Science,Medlineの総合的な文献検索
- HIV がん患者におけるICIの有効性を評価した研究を含む.
- 主要アウトカム:ICIの予後効果,無進行生存期 (PFS),全生存期 (OS)
主要な成果:
- 19件の研究 (2011年−2024年) の107件の症例が検討されました.
- プログラム死亡1型 (PD-1型) 阻害剤は, 27. 1% の部分応答, 23. 36% の安定した疾患, 6. 54% の完全応答, 34. 57% の疾患進行を示した.
- ほとんどの症例ではHIVウイルスの負荷は安定した.
結論:
- PD- 1 阻害剤は,HIVに関連した悪性腫瘍において,一般患者と同様の安全性プロファイルを示しています.
- 病気の進行は懸念され,最適化された患者の選択が必要である.
- PLWHの治療ガイドラインと公平な免疫療法へのアクセスには,さらなる試験が重要です.
さらに関連する動画
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
672
関連する概念動画
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
